Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials
In 2017, the FDA issued a warning letter to LifeVantage for making unsubstantiated claims about the ability of its products to cure diseases
This study was limited in scope: Conducted on 24 rats, not humans Administered a single dose Designed only to demonstrate that some absorption is possible Importantly, the study itself includes this disclaimer: This proof-of-concept study is not intended to provide guidance on the sublingual dosing of semaglutide in humans, or dosing conversion from other forms to sublingual administration. This means the only research behind these products cannot confirm whether they work in humans or provide guidance on appropriate dosing
Some providers charge more at higher doses, which means your costs escalate precisely when you need the most medication
Her examination shows the presence of acanthosis nigricans on her neck and armpits
Fatigue and energy fluctuations Fatigue is a frequently reported side effect, particularly in the first few weeks of treatment and after dose escalations